Genedata announces new data analysis platform for oncology drug discovery at SLAS2014

AstraZeneca and Genedata will detail a data analysis platform for compound combination experiments in oncology and other therapeutic areas

Lloyd Dunlap
Register for free to listen to this article
Listen with Speechify
SAN DIEGO, Calif.—Genedata, a provider of advanced software solutions for drug discovery and life science research, today announced that at SLAS2014 it will showcase results from its collaboration with AstraZeneca on the data analysis of compound combination experiments. This collaboration created the new Genedata Screener® for Compound Combinations platform, which provides for high-throughput combination screening capabilities within AstraZeneca's Oncology iMed unit. Automating and standardizing the data analysis of combination screening experiments, Genedata Screener accelerates discovery of new compound combination therapies by enabling high-throughput combination profiling, the company stated in a press release. The platform will be featured in a joint poster session ("Accelerating Discovery of Novel Drug Combination Therapies Using High-Throughput Combination Profiling—Challenges and Effective Solutions"), and Genedata Screener for Compound Combinations will be previewed in two tutorials (January 20; 2:00pm - 2:45pm: "Genedata Screener: Mastering complex screening technologies”; January 21; 2:00pm - 2:45pm: "Genedata Screener Compound Synergy Extension: Complex raw data to transparent results in less than 30 minutes"), as well as being demonstrated in the Genedata booth (#551)
"Our successful collaboration with AstraZeneca demonstrates our expertise in solving complex data analysis challenges, drives the development of Genedata Screener as the platform of choice for all plate-based screening data analysis, and shows how we create sustainable and cost-effective solutions for our customers," noted Dr. Othmar Pfannes, CEO of Genedata. "We are committed to a business model that delivers innovative data analysis procedures, enabling our customers to become more efficient in their research processes and maximizing the return on investments in their technology platforms."
Genedata Screener is currently used by the majority of the top 25 global pharmaceutical companies as their main platform for the analysis and management of all plate-based screening data, according to the company. Capitalizing on the open architecture of Genedata Screener and its proven efficiency in a broad range of screening workflows, the Genedata collaboration with AstraZeneca extends Genedata Screener functionality to a new range of applications of increasing importance for innovative oncology research.
Identifying effective and disease-specific combinations of cancer therapies through in vitro cell-based assays requires “industrial-scale screening.” As the number of tests increases exponentially with the number of compounds in a study, a high-throughput screening infrastructure with automated yet flexible analytical tools is needed for rapid profiling of even a modest number of drugs in combination studies. For example, testing all combinations of 30 compounds across 20 cell lines requires screening of over 9,000 384-well plates, which presents a computational challenge that can take weeks of data analysis. This data analysis bottleneck is reportedly removed by Genedata Screener for Combination Screening. It quickly analyzes screening results with standardized yet customizable parameter settings to calculate, combine, and visualize experimental data and identify the best combinations. Within hours versus weeks, researchers have scientifically validated results.
The new platform enables analysis of all experimental data generated throughout the process—from raw instrument data to final synergy score calculations for all combinations in a study. While it offers an advanced degree of automation, efficiency and integration with an existing screening data infrastructure, Genedata Screener also provides interactive data quality assessment and continuous data review. Results scoring uses various published mathematical models (i.e. HSA, Loewe, Bliss), and new, yet reliable, methods for determining response with fast, accurate and robust assessments of synergistic effects, Genedata claims.
Genedata’s goal is to transform data into intelligence with a portfolio of advanced software solutions, which make research data accessible and understandable and research processes more efficient. These solutions are used worldwide by leading pharmaceutical, industrial, and agricultural biotechnology companies as well as academic research organizations. Genedata innovations aim to enable scientific discovery that fights disease and improves health and quality of life worldwide. Founded in 1997, Genedata is headquartered in Switzerland, and has offices in Germany, Japan, and the U.S.
Source: Genedata

Lloyd Dunlap

Subscribe to Newsletter
Subscribe to our eNewsletters

Stay connected with all of the latest from Drug Discovery News.

March 2024 Issue Front Cover

Latest Issue  

• Volume 20 • Issue 2 • March 2024

March 2024

March 2024 Issue